Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04559230 · ClinicalTrials.gov registry record · Phase 2
Sacituzumab Govitecan in Recurrent Glioblastoma
A Phase 2 study of Recurrent Glioblastoma, sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 3
- Study locations
NCT04559230 is a Phase 2 study of Recurrent Glioblastoma that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 32 participants, below the 68-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (53% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT04559230, a Phase 2 study of Recurrent Glioblastoma, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is an open-label single arm study. All patients will receive the study drug. The aim of the study is to compare overall survival (OS) of patients with recurrent brain tumor, known as Glioblastoma (GBM) having high levels of a protein, Trophoblast cell surface antigen 2 (Trop-2), expression on treatment with Sacituzumab Govitecan (SG) versus lomustine only which has been used in the past.
Conditions Studied
Interventions
- DRUG Sacituzumab Govitecan
Study Locations (3)
Texas
- Texas Oncology Austin - Austin
- University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center - San Antonio
Ohio
- Cleveland Clinic Taussig Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-01-06 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04559230
The ClinicalTrials.gov registry entry for NCT04559230 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 68-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (53% lower). The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Sacituzumab Govitecan is the first listed.
NCT04559230 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Texas, Ohio.
Frequently Asked Questions
What is clinical trial NCT04559230 about?
NCT04559230 is a clinical study titled "Sacituzumab Govitecan in Recurrent Glioblastoma". This is an open-label single arm study. All patients will receive the study drug. The aim of the study is to compare overall survival (OS) of patients with recurrent brain tumor, known as Glioblastoma (GBM) having high levels of a protein, Trophoblast cell surface antigen 2 (Trop-2), expression on t...
What is the current status of trial NCT04559230?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2022-01-06. Estimated completion is 2026-08.
What conditions does trial NCT04559230 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma.
What interventions are being tested in trial NCT04559230?
The interventions under investigation include: Sacituzumab Govitecan (DRUG).
Who is sponsoring clinical trial NCT04559230?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04559230 being conducted?
This trial has 3 study locations across Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
RECRUITING · Phase 2
-
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
RECRUITING · Phase 2
-
OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial
RECRUITING · Phase 2
-
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
RECRUITING · Phase 2
-
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.